Maria Chaudhry, MBBS
A variety of triplet and quadruplet regimens continue to be investigated and move through the pipeline in newly diagnosed multiple myeloma as well as in the relapsed/refractory setting, explained Maria Chaudhry, MBBS.
Newly diagnosed patients are also being treated with quadruplet regimens. In the phase II GRIFFIN trial, investigators examined the addition of daratumumab to bortezomib (Velcade) and Rd (D-RVd) in transplant-eligible patients with newly diagnosed multiple myeloma. At a median follow-up of 22.1 months, results showed that the stringent complete response (sCR) rate was 62.6% with daratumumab plus D-RVd compared with 45.4% with RVd alone.2
In the relapsed/refractory setting, Chaudhry said there is a plethora of options, though the triplet regimens have not yet been compared head to head; therefore, the superiority among them is unclear.
... to read the full story